Pembrolizumab improves PFS and QoL in dMMR advanced endometrial cancer
Published on 26 October 2026
Dr Brian Slomovitz speaks to ecancer about KEYNOTE-C93/GOG-3064/ENGOT-en15, a phase 3, randomised, open-label study of first-line pembrolizumab versus carboplatin plus paclitaxel in mismatch repair-deficient (dMMR) advanced or recurrent endometrial carcinoma.
This compared single-agent pembrolizumab with carboplatin and paclitaxel chemotherapy, highlighting improved progression-free survival, duration of response, and quality of life with pembrolizumab.
He concludes that a chemotherapy-free pembrolizumab regimen is a reasonable option for this patient subset.
This information is intended for health care professionals only. The information is not intended for US health care professionals.